Optimization or Enhancement? Where the Line Actually Falls

Testosterone, nandrolone, and why the same number on a lab report can mean two completely different things.

---

For most of modern history, the tools that fine-tune human hormones lived behind a velvet rope. Elite athletes had team physicians. The wealthy had concierge endocrinologists. Everyone else got a five-minute appointment, a "your levels are normal," and a shrug.

That gap is closing — and that's a good thing. But access without understanding is its own kind of risk. As testosterone therapy, peptide protocols, and compounds like nandrolone move into the mainstream conversation, one distinction gets blurred more than any other: the difference between optimization and enhancement.

They are not the same thing. They are not even close. And the confusion between them is where people get hurt — either by chasing supraphysiologic performance under the banner of "wellness," or by dismissing legitimate, monitored therapy as "just steroids." At DeNovo Longevity, closing the gap between elite longevity medicine and everyday people means giving you the framework the experts actually use. So let's draw the line clearly, with real numbers.

A tale of two dose-response curves

The single most useful piece of research here comes from a series of studies led by Dr. Shalender Bhasin in the 1990s and early 2000s. His team did something clever: they suppressed men's natural testosterone production entirely, then added back fixed weekly doses. Because nothing was being made internally, the blood levels they measured mapped cleanly onto the dose given.

Here's what they found, simplified to the essentials:

Weekly testosterone dose	Approximate blood level (trough)	Where it sits
25 mg	~250 ng/dL	below normal
50 mg	~300 ng/dL	low-normal
125 mg	~540–700 ng/dL	mid-normal (a typical therapy target)
300 mg	~1,345 ng/dL	supraphysiologic
600 mg	~2,370 ng/dL	frank enhancement

Two things jump out. First, the relationship is real and measurable — more drug, more hormone, more muscle. Second, and more important: somewhere around the 1,000 ng/dL mark, the body crosses out of the range it could ever produce on its own.

Researchers have proposed that there are essentially two different dose-response curves. One operates in the deficient-to-normal range, where restoring testosterone relieves symptoms and benefits plateau near the top of the normal range. The other operates in the supraphysiologic range — a separate mechanism that keeps adding muscle by flooding the system far beyond anything natural physiology produces.

That second curve is the territory of enhancement. The first is the territory of optimization. Same molecule. Different universe.

What enhancement actually looks like

To understand the line, it helps to see how far the enhancement side runs from the medical side.

A standard medical replacement dose lands around 75–100 mg of testosterone per week, aiming to put a deficient man back into the mid-normal range. Now compare that to what's documented in surveys of performance users:

• In one contemporary survey, 81% of users reported taking 400 mg or more per week — four to five times a replacement dose.
• Use frequently begins at 500–1,000 mg per week, roughly five to ten times the medical dose.
• Across the broader literature, self-reported weekly doses range from 250 all the way to 5,000 mg.
• And it's rarely one drug. Over 90% of users report stacking at least one additional compound on top of testosterone.

This is the part worth sitting with. Enhancement isn't "a slightly higher dose of the same therapy." It's a fundamentally different practice: multiple compounds, self-administered, pushing blood levels two to five times above anything the body could manufacture, usually without lab monitoring. The goal isn't to restore a system to balance. It's to override it.

Why your total testosterone number can lie

Here's where most articles oversimplify — and where the truth is actually more interesting.

You might look at that table and assume blood level is a clean readout of androgen exposure. It isn't. Two men can walk in with an identical total testosterone of 2,000 ng/dL and have completely different physiology. Understanding why is the key to understanding optimization at all.

Start with a basic fact: the testosterone in your blood isn't all available to your tissues. Roughly 98% of it is bound to proteins — mostly one called sex hormone-binding globulin (SHBG) — and held in circulation. Only the small free and loosely-bound fraction can actually enter cells and do anything. Total testosterone counts all of it, bound and unbound alike.

Now consider a man with naturally high SHBG. Because SHBG grips testosterone tightly and protects it from being cleared, his testosterone accumulates in the bound pool. His total number climbs — but his free, usable testosterone can stay perfectly normal, or even low. He may need a much higher total number just to achieve an ordinary amount of active hormone. A modest weekly dose can produce a strikingly high total reading in someone like this, while the androgen his tissues actually experience remains entirely physiologic.

This is why a total testosterone in isolation can be deeply misleading. It cuts both ways: high SHBG inflates the number, low SHBG deflates it. There are documented cases of men with "normal-looking" totals who were genuinely deficient once their free hormone was measured directly — and the reverse.

There's a second layer: how an individual metabolizes testosterone. Two enzymes compete for it. One, 5-alpha-reductase, converts testosterone into DHT — the most potent androgen, the one most responsible for the strong "androgenic" effects. The other, 5-beta-reductase, routes testosterone toward an essentially inactive metabolite headed for excretion. People vary enormously in which pathway dominates.

Someone who runs heavily down the 5-beta (less androgenic) pathway converts a smaller share of their testosterone into potent active androgen. To achieve the same tissue-level effect — the same relief from low-testosterone symptoms — they may need more circulating hormone, simply because less of it becomes the active form. For that person, a higher total number can correspond to a balanced, physiologic androgen load rather than an excessive one. You can often see the consistency in the supporting markers: when blood-building (hematocrit), estradiol, and DHT all sit in optimal ranges at a total level that would over-stimulate someone else, the picture hangs together.

This is the heart of the optimization mindset. Total testosterone is a necessary but insufficient marker. "Optimal" is defined at the level of the whole system — free and bioavailable testosterone, DHT, estradiol, SHBG, blood count, and how a person actually feels and functions. Because individuals differ in binding-protein status and metabolism, the total number that corresponds to a balanced, optimized system varies widely from one person to the next.

A crucial caveat, in the spirit of intellectual honesty: a high total testosterone earns scrutiny, not a free pass. The reassuring interpretation only holds if the free hormone and DHT are confirmed to be in range — not also elevated — ideally on a gold-standard (mass spectrometry) assay, with blood draws timed consistently, and with long-term monitoring of hematocrit, estradiol, ApoB, and blood pressure. This is precisely why individualized optimization belongs in a monitored, physician-collaborated setting, and why a number that works beautifully for one person is never a target someone else should chase.

Nandrolone: one molecule, two completely different stories

Nandrolone — often called by the brand name Deca-Durabolin — is the cleanest illustration of the optimization/enhancement divide, because the very same compound has both a documented low-dose clinical use and a well-characterized high-dose abuse pattern.

On the optimization side, the most cited reference is a 2020 study by Tatem and colleagues. Men already on testosterone therapy who suffered from joint pain added a low dose of nandrolone — a median of about 110 mg per week, roughly half their testosterone dose. Nearly three-quarters reported marked improvement, pain scores fell by about half on average, and no adverse events were recorded. Historically, nandrolone's therapeutic window has run around 50–200 mg per week for conditions like anemia and osteoporosis.

The reason this works at low doses comes down to chemistry. Nandrolone is more "anabolic" relative to its "androgenic" activity than testosterone — its muscle-and-tissue-building effect is favorable relative to its masculinizing effect — because its metabolites behave differently in different tissues. That's also why it has been studied for tendon and joint healing.

It is not without trade-offs, and an honest piece names them: nandrolone is progestogenic, it suppresses the natural hormonal axis, and because it can lower DHT, used alone it can cause sexual side effects — which is exactly why the joint-health protocol pairs it with testosterone rather than replacing it.

The enhancement side of the same molecule? Doses of 200–600 mg per week and up, stacked with other compounds. The authors of the joint-pain study make the point themselves: nearly everything frightening in nandrolone's safety record comes from abuse-level dosing — in animal models, harms appeared at roughly twenty times the clinical dose. The compound didn't change. The dose, the intent, and the monitoring did.

It's not just a men's conversation

Optimization-versus-enhancement applies to women too — at roughly one-tenth the scale, and with an active debate worth knowing about.

Testosterone is, in fact, the most abundant active sex hormone in women across the lifespan, and its decline contributes to symptoms that are frequently misattributed: fatigue, low mood, cognitive fog, loss of muscle and bone, and reduced libido. The clinical research uses doses around one-tenth of male products, aiming for the normal premenopausal female range. At those physiologic doses, masculinizing effects are uncommon, and the androgenic side effects that can occur — like acne or unwanted hair — are dose- and time-dependent and largely reversible.

Push into enhancement-level dosing, and that changes. Virilization — voice deepening, significant hair changes — becomes a real risk, and some of those changes do not reverse. As with men, the same molecule is medicine in one dose range and a different proposition entirely in another. (There's a genuine professional disagreement here, too: some clinicians argue for individualizing to end-organ response rather than to a fixed serum target — the same "the number isn't the whole story" theme that runs through this entire piece.)

The real dividing line

If you take one thing from this, let it be that dose alone isn't the definition — it's just the most measurable proxy for three things that actually separate optimization from enhancement:

1. Intent. Optimization restores a system to a defined, physiologic range. Enhancement deliberately exceeds any range the body could reach on its own.
2. Monitoring. Optimization is a single agent, titrated against comprehensive labs and symptoms, adjusted over time. Enhancement is typically multiple compounds, self-directed, unmonitored.
3. Risk posture. Optimization works to minimize adverse effects as a condition of treatment. Enhancement accepts known, escalating risk in exchange for maximal output.

A blood level is a snapshot. These three things are the whole photograph.

The DeNovo Longevity approach: test, don't guess

Everything above points to the same conclusion. There is no universal "right number." There is only your number — the level at which your free testosterone, your DHT, your estradiol, your blood count, and your day-to-day function all line up. Finding it isn't guesswork, and it isn't a chart you copy from someone else. It's measurement, interpretation, and patient adjustment, in partnership with a qualified medical provider.

That's the difference between treating yourself like a population average and treating yourself like what you actually are: an experiment of one. Elite medicine has always understood this. Our mission is to make that understanding — and the rigor behind it — available to everyone, not just the people who could once afford the velvet rope.

Optimization is not a smaller version of enhancement. It's a different goal entirely. Know which one you're pursuing, measure honestly, and never let a single number on a page tell you the whole story.

---

Further reading

• Bhasin S, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. New England Journal of Medicine, 1996.
• Bhasin S, et al. Testosterone dose-response relationships in healthy young men. American Journal of Physiology — Endocrinology and Metabolism, 2001.
• Rasmussen JJ, et al. / Mayo Clinic Proceedings. Heavy Testosterone Use Among Bodybuilders, 2016.
• Tatem AJ, et al. Nandrolone decanoate relieves joint pain in hypogonadal men. Translational Andrology and Urology, 2020.
• Pan MM, Kovac JR. Beyond testosterone cypionate: evidence behind the use of nandrolone in male health and wellness. Translational Andrology and Urology, 2016.
• Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology & Metabolism, 2019.

---

This article is educational and is not medical advice. DeNovo Longevity, Inc. provides coaching and education and does not prescribe or dispense medications. Hormone and anabolic therapies carry real risks and should only be undertaken in collaboration with a qualified, licensed medical provider who can order and interpret the appropriate testing.